Article Text
Statistics from Altmetric.com
Commentary on: OpenUrlCrossRefPubMedWeb of Science
Context
Chronic heart failure (CHF) is common, affecting 1–2% of the population and 10% of people >70 years. Patients with CHF have an increased risk of thromboembolism. Those with atrial fibrillation (AF) should receive warfarin but whether CHF patients with sinus rhythm (SR), whose risk is 1.5–3.5%,1 should receive thromboprophylaxis is unclear.
Previous studies, Warfarin/Aspirin Study in Heart failure (warfarin, aspirin 300 mg daily, placebo),2 Heart failurE Long-term Antithrombotic Study (aspirin 325 mg daily or warfarin for patients with ischaemic heart disease (IHD) or warfarin or placebo in the non-ischaemics)3 and Warfarin and Antiplatelet Therapy in Chronic Heart failure (WATCH: warfarin, clopidogrel 75 mg daily, …
Footnotes
-
Competing interests None.